Gossamer Bio Announces Participation in 9th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO--()--Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25 at 9:30 a.m. ET.

A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the company’s website at https://ir.gossamerbio.com. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

Contacts

For Investors:
Argot Partners
212.600.1902
gossamerbio@argotpartners.com

For Media:
Argot Partners
David Rosen
212.600.1902
david.rosen@argotpartners.com

Contacts

For Investors:
Argot Partners
212.600.1902
gossamerbio@argotpartners.com

For Media:
Argot Partners
David Rosen
212.600.1902
david.rosen@argotpartners.com